The Alzheimer’s Global Platform Foundation® (GAP) is pleased to welcome Spear Bio, a biotechnology company pioneering wash-free ultrasensitive immunoassay technology, to the Bio-Hermes-002 study. This collaboration will enhance this unique observational platform study that compares blood-based and digital biomarkers across a wide range of clinical cognitive states, MRI and PET imaging, and multiple races and ethnicities to generate data that can help predict, detect, and diagnose Alzheimer’s disease and related dementias.
The Bio-Hermes-002 study is collecting data reflecting the performance of each biomarker in the study, or combination of biomarkers, to assess, diagnose or predict the presence of a variety of pathologies associated with Alzheimer’s disease and related dementias, including amyloid and tau in the brain.
In Bio-Hermes-002, Spear Bio will provide blood-based biomarker analysis results using SPEAR UltraDetect™ assay platform offering molecular sensitivity from 1 uL diluted sample and superior wash-out homogenous specificity in an effort to change the paradigm for early-stage disease diagnosis and monitoring for Bio-Hermes-002, building on findings from Bio-Hermes-001.
We are proud to have Spear Bio as a valued partner in the Bio-Hermes-002 study. Their technology platform is consistent with our goal to catalyze and scale early stage disease diagnosis and monitoring, thereby transforming the way we treat patients and conduct clinical trials for Alzheimer’s and related dementias. By advancing biomarker detection, we hope to accelerate important progress for individuals and families affected by these conditions.”
John Dwyer, President, GAP
Data from the Bio-Hermes-002 study will be stored on the AD workbench by the Gates Ventures Alzheimer’s Disease Data Initiative (ADDI). AD Workbench is a global, secure, cloud-based data sharing and analysis environment that enables researchers around the world to share, access and analyze data across multiple platforms.
Spear Bio joins a list of industry leaders who are partners in this study, including Biogen and Eli Lilly and Company, IXICO and Roche along with a growing list of outstanding partners providing blood-based or digital biomarker assessments for Bio-Hermes-002. Partners to date include AINOSTICS, Alamar Biosciences, Beckman Coulter Diagnostics, Cambridge Cognition Limited, Cognivue, Cumulus Neuroscience Limited, Fujirebio, iLoF, LifeArc, Linus Health, Lucent Diagnostics–a Quanterix, ViewMinibird brand.
